Harris, D., Brungs, D., Ladwah, R., Mant, A., McGrath, M., Tazbirkova, A., Akopov, A., Fadeeva, N., Kasparov, B., Kovalenko, N., Kozlov, V., Moiseenko, F., Oschepkov, V., Koralewski, P., Kowalski, D., Lugowska, I., Charoentumn, C., Dechaphunkul, A., Sriuranpong, V., Oliviero, J., & Clingan, P. (n.d.). 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. Journal for immunotherapy of cancer, 8, A242–A243. http://access.bl.uk/ark:/81055/vdc_100144710526.0x000002